Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Healthcare resource utilization and costs in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 25, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB206.

RATIONALE: Real-world data on eosinophilic granulomatosis with polyangiitis (EGPA) are sparse. This retrospective analysis of US administrative health insurance claims data (MarketScan® or Medicare) quantified the impact of EGPA versus severe uncontrolled asthma (SUA) on healthcare resource utilization (HCRU) and health insurer payment costs.

METHODS: Patients with newly diagnosed EGPA during 2017–2021 with ≥12 months of continuous pre-diagnostic health plan enrolment and ≥1 day of post-diagnostic follow-up were included and matched with ≤4 people with SUA based on demographic and enrollment characteristics. Follow-up ran from first observed EGPA diagnosis until health plan disenrollment/database end. Annualized HCRU and associated health insurer payment costs (not including deductible, co-pay or co-insurance) were assessed overall and by care setting.

RESULTS: 182 patients with EGPA were matched to 640 with SUA. Patients with EGPA versus SUA were more likely (p<0.001) to have a hospital inpatient stay (46% vs 16%) or outpatient visit (93% vs 74%), and had a higher mean number of days/year with a doctor’s visit (25 vs 16) and pharmacy claims/year (56 vs 46). Patients with EGPA versus SUA had higher healthcare-related costs ($118,127 vs $22,286, p<.001), mainly driven by higher costs for inpatient stays ($47,980 vs $4,172, p=.006), outpatient hospital visits ($27,714 vs $5,618, p<.001), doctor office visits ($11,112 vs $2,435, p<.001), and pharmacy costs ($24,753 vs $8,058, p<.001).

CONCLUSIONS: Patients with EGPA had higher annualized HCRU and health insurer payment costs than those with SUA. EGPA placed a higher economic burden on patients and the healthcare system than SUA.

Share on: